Drug intelligence / Profile preview

SYP-2566

Development stage: Preclinical
Lead developer: Samyang Holdings Biopharm Group
Modality: mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Nanoparticles → Drug Delivery Systems
Administration: Intrathecal, Intravenous

Overview

SYP-2566 is a preclinical mRNA-based therapeutic candidate being developed by Samyang Holdings Biopharm Group. It utilizes the company's proprietary SENS™ (Samyang Elucidating Nanoparticle System) delivery platform, which is a non-viral delivery technology designed to facilitate the transport of nucleic acids. Specifically, SYP-2566 is engineered for delivery to the central nervous system (CNS), aiming to address neurological disorders by enabling the expression of therapeutic proteins within brain or spinal cord tissues. As of early 2024, the program remains in the preclinical stage, and the specific target gene or primary indication within the CNS space has not been publicly disclosed.

Beyond the preview

Go deeper on SYP-2566.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SYP-2566.

Explore the full profile